399 related articles for article (PubMed ID: 16048833)
41. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
42. Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors.
Soar K; Turner JJ; Parrott AC
J Psychopharmacol; 2006 May; 20(3):417-24. PubMed ID: 16574716
[TBL] [Abstract][Full Text] [Related]
43. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine.
Karlsen SN; Spigset O; Slørdal L
Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):15-24. PubMed ID: 18047478
[TBL] [Abstract][Full Text] [Related]
44. Ecstasy use and self-reported disturbances in sleep.
Ogeil RP; Rajaratnam SM; Phillips JG; Redman JR; Broadbear JH
Hum Psychopharmacol; 2011 Oct; 26(7):508-16. PubMed ID: 21953704
[TBL] [Abstract][Full Text] [Related]
45. Incidence and patterns of polydrug use and craving for ecstasy in regular ecstasy users: an ecological momentary assessment study.
Hopper JW; Su Z; Looby AR; Ryan ET; Penetar DM; Palmer CM; Lukas SE
Drug Alcohol Depend; 2006 Dec; 85(3):221-35. PubMed ID: 16730923
[TBL] [Abstract][Full Text] [Related]
46. The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney.
Campbell GA; Rosner MH
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1852-60. PubMed ID: 18684895
[TBL] [Abstract][Full Text] [Related]
47. The rise of club drugs in a heroin society: the case of Hong Kong.
Joe Laidler KA
Subst Use Misuse; 2005; 40(9-10):1257-78. PubMed ID: 16048816
[TBL] [Abstract][Full Text] [Related]
48. Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users.
Stuerenburg HJ; Petersen K; Bäumer T; Rosenkranz M; Buhmann C; Thomasius R
Neuro Endocrinol Lett; 2002 Jun; 23(3):259-61. PubMed ID: 12080289
[TBL] [Abstract][Full Text] [Related]
49. Is ecstasy perceived to be safe? A critical survey.
Gamma A; Jerome L; Liechti ME; Sumnall HR
Drug Alcohol Depend; 2005 Feb; 77(2):185-93. PubMed ID: 15664720
[TBL] [Abstract][Full Text] [Related]
50. Alcohol use and risk taking among regular ecstasy users.
Breen C; Degenhardt L; Kinner S; Bruno R; Jenkinson R; Matthews A; Newman J
Subst Use Misuse; 2006; 41(8):1095-109. PubMed ID: 16798678
[TBL] [Abstract][Full Text] [Related]
51. An investigation into the sub-acute effects of ecstasy on aggressive interpretative bias and aggressive mood - are there gender differences?
Hoshi R; Pratt H; Mehta S; Bond AJ; Curran HV
J Psychopharmacol; 2006 Mar; 20(2):291-301. PubMed ID: 16510487
[TBL] [Abstract][Full Text] [Related]
52. Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users.
Morefield KM; Keane M; Felgate P; White JM; Irvine RJ
Addiction; 2011 Jul; 106(7):1293-300. PubMed ID: 21320226
[TBL] [Abstract][Full Text] [Related]
53. The association between the negative effects attributed to ecstasy use and measures of cognition and mood among users.
Fisk JE; Montgomery C; Murphy PN
Exp Clin Psychopharmacol; 2009 Oct; 17(5):326-36. PubMed ID: 19803632
[TBL] [Abstract][Full Text] [Related]
54. Intensity dependence of auditory evoked dipole source activity in polydrug ecstasy users: evidence from an 18 months longitudinal study.
Daumann J; Till B; Fischermann T; Rezk M; Gouzoulis-Mayfrank E
J Psychopharmacol; 2006 Mar; 20(2):236-44. PubMed ID: 16510481
[TBL] [Abstract][Full Text] [Related]
55. Increased risk of "club" drug use among gay and bisexual high school students in British Columbia.
Lampinen TM; McGhee D; Martin I
J Adolesc Health; 2006 Apr; 38(4):458-61. PubMed ID: 16549313
[TBL] [Abstract][Full Text] [Related]
56. [Comment on R. Thomasius, M. Schmolke, D. Kraus: MDMA ("Ecstasy") use--an overview of psychiatric and medical sequelae].
Gouzoulis-Mayfrank E; Hermle L; Kovar KA; Sass H
Fortschr Neurol Psychiatr; 1999 Dec; 67(12):574-6. PubMed ID: 10683753
[No Abstract] [Full Text] [Related]
57. Patterns of use and harm reduction practices of ecstasy users in Australia.
Allott K; Redman J
Drug Alcohol Depend; 2006 Apr; 82(2):168-76. PubMed ID: 16226850
[TBL] [Abstract][Full Text] [Related]
58. Theory of planned behaviour and ecstasy use: an analysis of moderator-interactions.
Umeh K; Patel R
Br J Health Psychol; 2004 Feb; 9(Pt 1):25-38. PubMed ID: 15006199
[TBL] [Abstract][Full Text] [Related]
59. Prevalence and correlates of current depressive symptomatology among a community sample of MDMA users in Ohio.
Falck RS; Wang J; Carlson RG; Siegal HA
Addict Behav; 2006 Jan; 31(1):90-101. PubMed ID: 15922511
[TBL] [Abstract][Full Text] [Related]
60. What's in a Name? Correlates of Ecstasy Users Knowing or Agreeing that Molly is Ecstasy/MDMA.
Palamar JJ
J Psychoactive Drugs; 2018; 50(1):88-93. PubMed ID: 28937933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
